01:50 , Mar 8, 2019 |  BC Innovations  |  Emerging Company Profile

Janpix picks STAT inhibitors for blood cancers

Janpix is developing STAT3 and STAT5 inhibitors that could treat hematologic malignancies with greater durability and lower risk of side effects than other inhibitors of the JAK-STAT pathway. Janpix Inc. in-licensed its family of small...
18:58 , Feb 22, 2019 |  BC Week In Review  |  Clinical News

Pfizer reports increase in lung clots, death with high-dose Xeljanz in postmarket study

Pfizer Inc. (NYSE:PFE) disclosed an increase in pulmonary embolisms and deaths among rheumatoid arthritis patients receiving the twice-daily 10 mg dose of Xeljanz tofacitinib in the A3921133 postmarketing CV safety trial. The pharma said Feb....
22:49 , Feb 20, 2019 |  BC Extra  |  Clinical News

Pfizer reports increase in lung clots, death with high-dose Xeljanz in postmarket study

Pfizer Inc. (NYSE:PFE) disclosed an increase in pulmonary embolisms and deaths among rheumatoid arthritis patients receiving the twice-daily 10 mg dose of Xeljanz tofacitinib in the A3921133 postmarketing CV safety trial. The pharma said Tuesday...
02:50 , Nov 2, 2018 |  BC Innovations  |  Targets & Mechanisms

Rethinking definitions of autoimmune disease

The autoimmune field is dialing up its search for better biomarkers as it seeks to make the next step change from the targeted therapies that overtook blanket immunosuppressants. The question is whether autoimmunity might follow...
03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate...
19:25 , Jun 1, 2018 |  BC Week In Review  |  Clinical News

Pfizer's Xeljanz gets label extension to include UC

FDA approved an sNDA for Xeljanz tofacitinib from Pfizer Inc. (NYSE:PFE) to treat adults with moderately to severely active ulcerative colitis. The agency said Xeljanz is the first oral drug approved for chronic use in...
18:59 , May 30, 2018 |  BC Extra  |  Company News

Pfizer's Xeljanz gets label extension to include UC

FDA approved an sNDA for Xeljanz tofacitinib from Pfizer Inc. (NYSE:PFE) to treat adults with moderately to severely active ulcerative colitis. The agency said Xeljanz is the first oral drug approved for chronic use in...
16:33 , Apr 20, 2018 |  Regulatory  |  Regulatory

FDA says Olumiant's thrombosis signal not a JAK class effect

FDA reviewers raised concerns over a possible increased risk of thrombosis with rheumatoid arthritis candidate Olumiant baricitinib from Eli Lilly and Co. (NYSE:LLY) and partner Incyte Corp. (NASDAQ:INCY). In briefing documents released on April 19...
23:46 , Apr 19, 2018 |  BC Extra  |  Company News

FDA says Olumiant's thrombosis signal not a JAK class effect

FDA reviewers raised concerns over a possible increased risk of thrombosis with rheumatoid arthritis candidate Olumiant baricitinib from Eli Lilly and Co. (NYSE:LLY) and partner Incyte Corp. (NASDAQ:INCY). In briefing documents released Thursday ahead of...
18:36 , Mar 9, 2018 |  BC Week In Review  |  Clinical News

FDA GI panel backs Pfizer's Xeljanz for ulcerative colitis

FDA’s Gastrointestinal Drugs Advisory Committee voted unanimously in favor of approving twice-daily 10 mg Xeljanz tofacitinib from Pfizer Inc. (NYSE:PFE) to treat adults with moderately to severely active ulcerative colitis. The panel also voted 8-7...